Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

G Park K, Lee JH, Soriano E, Choi M, Bao K, Katagiri W, et al. Rapid and Selective Targeting of Heterogeneous Pancreatic Neuroendocrine Tumors. iScience. 2020;23(4):101006.

Yang GC, Fried KO, Scognamiglio T. Can cytology and the Thyroid Imaging, Reporting, and Data System (TI-RADS) identify noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) before surgery? J Am Soc Cytopathol. 2020;9(3):159-165.

Sadick N, Magro C. Response to Letter to the Editor. J Am Acad Dermatol. 2020.

Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun. 2020;11(1):1987.

Shi CY, Kingston ER, Kleaveland B, Lin DH, Stubna MW, Bartel DP. The ZSWIM8 ubiquitin ligase mediates target-directed microRNA degradation. Science. 2020;370(6523).

Dillard A, DeSimone RA, Hsu Y-, Ma L, Vasovic L, Racine-Brzostek S, et al. Flat line in the blood bank: code H (hyperfibrinolysis)? Transfusion. 2020;60(9):1894-1896.

Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, et al. Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2020;585(7826):E20.

Zhang T, Na JH, Li S, Chen Z, Zhang G, Pang S, et al. Functional impact of cancer patient-associated Bcl-xL mutations. MedComm (Beijing). 2020;1(3):328-337.

Patel SS, Weinberg OK. Diagnostic workup of acute leukemias of ambiguous lineage. Am J Hematol. 2020;95(6):718-722.

Cushing MM, Haas T, Karkouti K, Callum J. Which is the preferred blood product for fibrinogen replacement in the bleeding patient with acquired hypofibrinogenemia-cryoprecipitate or fibrinogen concentrate? Transfusion. 2020;60 Suppl 3:S17-S23.